OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
THC
Tenet Healthcare Corporation
THC has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
THC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
THC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over THC in the historical PE scenario, which offers more potential upside but is not a forecast.
THC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $207 | -28% |
| Current | 8.3x | $287 | — |
| Fair | 11x | $365 | +27% |
| Forward | 14x | $287 | — |
| Expensive | 17x | $590 | +106% |
Historical ranges are pointers, not guarantees.
THC's PE is in its cheap range at 8.3x. On analysts' estimates for next year's earnings, today's price would be 14x, in its expensive range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over THC on the outlook, with more favorable valuation and revenue expectations.
THC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect THC's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
THC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.30 | -41% |
| Q3 2026 | $34.48 | +129% |
| Q2 2026 | $25.93 | +61% |
| Q1 2026 | $19.23 | +23% |
| Q4 2025 | $15.49 | -53% |
| Q3 2025 | $15.06 | -52% |
| Q2 2025 | $16.09 | -41% |
| Q1 2025 | $15.59 | -40% |
| Q4 2024 | $32.70 | +473% |
THC earned $34.48 per share over the past year, up 129% from the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over THC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
THC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.6B | +6.5% |
| Q2 2026 | $5.6B | +6.8% |
| Q1 2026 | $5.4B | +2.8% |
| Q4 2025 | $5.5B | +9% |
| Q3 2025 | $5.3B | +3.3% |
| Q2 2025 | $5.3B | +3.3% |
| Q1 2025 | $5.2B | -2.7% |
| Q4 2024 | $5.1B | -5.7% |
THC's revenue has grown year over year for six quarters in a row: $5.6B last quarter, up 6.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +14 points |
| Q2 2026 | 27% | +11 points |
| Q1 2026 | 24% | +6.1 points |
| Q4 2025 | 15% | -0.8 points |
| Q3 2025 | 17% | -4.5 points |
| Q2 2025 | 16% | +0.7 points |
| Q1 2025 | 18% | -43 points |
| Q4 2024 | 16% | +2.5 points |
THC has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over THC on cash flow, with more consistent year-over-year improvement.
THC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +39% |
| Q2 2026 | $417M | -44% |
| Q1 2026 | $1.5B | +128% |
| Q4 2025 | $367M | +$1B |
| Q3 2025 | $778M | -6.2% |
| Q2 2025 | $743M | +23% |
| Q1 2025 | $642M | +86% |
| Q4 2024 | -$661M | -207% |
THC generated $3.3B in free cash flow over the past year, up 122% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
THC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4% | -3.4M shares |
| 1 year | -9% | -8M shares |
| 3 years | -23% | -23.8M shares |
| 5 years | -26% | -28.2M shares |
| Available history | -22% | -22.8M shares |
THC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $255M |
| Q2 2026 | $1B |
| Q1 2026 | $318M |
| Q4 2025 | $198M |
| Q3 2025 | $93M |
| Q2 2025 | $747M |
| Q1 2025 | $348M |
| Q4 2024 | — |
THC spent $1.8B buying back its own shares over the past year, up 53% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over THC on leverage, with a lower net debt burden relative to earnings.
THC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 2.0x | Moderate |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.4x | Moderate |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 1.5x | Healthy |
THC's net debt is about 1.7 years of its operating earnings (EBITDA), down from 2.4 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
THC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.8 | Overbought |
| Stochastic | 73.5 | Neutral |
THC's weekly RSI is 72 (overbought) and its Stochastic is 73 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
THC PE vs Healthcare Sector
| Metric | THC | Sector median | Relative |
|---|---|---|---|
| PE | 8.3x | 26x | 68% below |
| PE % | 32 | 29 | 3 pts above |
THC has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
THC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $270.2 | 6.2% above |
| 20 week MA | $256.0 | 12% above |
| 50 week MA | $220.8 | 30% above |
| 100 week MA | $190.8 | 50% above |
| 200 week MA | $144.1 | 99% above |
THC is in an uptrend: it's above all five of its weekly moving averages, and 99% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over THC on returns for 2026, with the stronger performance.
THC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $38.3 | $40.1 | +4.9% |
| 2021 | $40.1 | $79.3 | +98% |
| 2022 | $79.3 | $46.6 | -41% |
| 2023 | $46.6 | $75.6 | +62% |
| 2024 | $75.6 | $128.0 | +69% |
| 2025 | $128.0 | $200.6 | +57% |
| 2026 YTD | $200.6 | $286.9 | +43% |
THC has finished higher in five of the last six years, four of them by more than 50%. It's up 43% so far in 2026.